The estimated Net Worth of Anup Marda is at least 1.74 百万$ dollars as of 18 October 2022. Mr. Marda owns over 50,000 units of Cabaletta Bio Inc stock worth over 213,000$ and over the last 5 years he sold CABA stock worth over 0$. In addition, he makes 1,528,630$ as Chief Financial Officer at Cabaletta Bio Inc.
Sign up
Mr. Marda CABA stock SEC Form 4 insiders trading
Anup has made over 1 trades of the Cabaletta Bio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of CABA stock worth 49,500$ on 18 October 2022.
The largest trade he's ever made was buying 50,000 units of Cabaletta Bio Inc stock on 18 October 2022 worth over 49,500$. On average, Anup trades about 7,143 units every 0 days since 2019. As of 18 October 2022 he still owns at least 50,000 units of Cabaletta Bio Inc stock.
You can see the complete history of Mr. Marda stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anup Marda biography
Anup Marda serves as Chief Financial Officer of the Company. From April 2001 to January 2019, Mr. Marda held positions at Bristol-Myers Squibb, including, most recently, as Vice President, Head of Global Corporate Financial Planning & Analysis, and previously as Head of Finance, R&D Operations and Head of Finance, R&D Portfolio Management and Global Medical from 2014 to 2018. Prior to this, Mr. Marda held the role of Executive Director, U.S. Pharmaceuticals from 2012 to 2014 and Assistant Treasurer, Capital Markets from 2008 to 2012. Mr. Marda received his MBA from the Krannert School of Business of Purdue University and his B.Tech in Chemical Engineering from the Indian Institute of Technology Bombay.
What is the salary of Anup Marda?
As the Chief Financial Officer of Cabaletta Bio Inc, the total compensation of Anup Marda at Cabaletta Bio Inc is 1,528,630$. There are no executives at Cabaletta Bio Inc getting paid more.
How old is Anup Marda?
Anup Marda is 42, he's been the Chief Financial Officer of Cabaletta Bio Inc since 2019. There are 13 older and 1 younger executives at Cabaletta Bio Inc. The oldest executive at Cabaletta Bio Inc is Richard Henriques, 64, who is the Independent Director.
What's Anup Marda's mailing address?
Anup's mailing address filed with the SEC is C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA, PA, 19104.
Insiders trading at Cabaletta Bio Inc
Over the last 5 years, insiders at Cabaletta Bio Inc have traded over 19,324,000$ worth of Cabaletta Bio Inc stock and bought 1,500,545 units worth 13,043,398$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Ventures V, L.P.5 Am Opport...、James E Deerfield Mgmt Iv, .... On average, Cabaletta Bio Inc executives and independent directors trade stock every 70 days with the average trade being worth of 632,329$. The most recent stock trade was executed by Gwendolyn Binder on 19 January 2024, trading 11,000 units of CABA stock currently worth 11,110$.
What does Cabaletta Bio Inc do?
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
What does Cabaletta Bio Inc's logo look like?
Complete history of Mr. Marda stock trades at Cabaletta Bio Inc
Cabaletta Bio Inc executives and stock owners
Cabaletta Bio Inc executives and other stock owners filed with the SEC include:
-
Anup Marda,
Chief Financial Officer -
Steven Nichtberger,
Chairman of the Board, President, Chief Executive Officer, Co-Founder -
Gwendolyn Binder-Scholl,
Executive Vice President, Science & Technology -
Dr. Steven A. Nichtberger M.D.,
Co-Founder, Chairman, CEO & Pres -
Dr. Steven A. Nichtberger,
Co-Founder, Chairman, CEO & Pres -
Dr. David J. Chang M.D., M.P.H.,
Chief Medical Officer -
Dr. Gwendolyn K. Binder,
Exec. VP of Science & Technology -
Richard Henriques,
Independent Director -
Catherine Bollard,
Independent Director -
Mark Simon,
Independent Director -
Brian Daniels,
Independent Director -
David Chang,
Chief Medical Officer -
J. Brian Stalter,
General Counsel -
Michael Gerard J.D.,
Gen. Counsel & Sec. -
Heather Harte-Hall M.Sc.,
Chief Compliance Officer -
Michael Gerard,
Gen. Counsel -
Dr. Samik Basu M.D.,
Chief Scientific Officer -
Martha O'Connor,
Chief HR Officer -
J. Brian Stalter J.D.,
Gen. Counsel -
Dr. Aimee Payne M.D., Ph.D.,
Co-Founder & Co-Chair of Scientific Advisory Board -
Dr. Michael C. Milone M.D., Ph.D.,
Co-Founder & Co-Chair of Scientific Advisory Board -
Anup Marda M.B.A.,
Chief Financial Officer -
Shawn Tomasello,
-
Scott C. Brun,
-
Gwendolyn Binder,
See Remarks -
Arun Das,
Chief Business Officer -
Group, Llc Green Jeremy Red...,
-
James E Deerfield Mgmt Iv, ...,
-
Ventures V, L.P.5 Am Opport...,
-
Michael Gerard,
General Counsel